Touchlight awarded runner-up in Spectator Economic Disruptor Award
Earlier this year, The Spectator and Julius Baer launched the inaugural Economic Disruptor Awards to celebrate the most creative entrepreneurs in the UK.
Over the past six months, over 100 nominations have been reviewed. On the 1st of November, the winners were announced at a gala dinner hosted by Andrew Neil, Chairman of The Spectator, and attended by over 120 guests from across the world of business.
The full list of regional winners – chosen for their creativity and scaling potential – were:
Pockit (London/the South)
Touchlight (runner-up – London/the South)
Warwick Music Group (Midlands)
rradar (North East)
AMPLYFI (North West & Wales)
See.Sense (Scotland & Northern Ireland)
Read the full article here.
- ENDS -
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
|Jonny Ohlson, CEO||Tim Watson / Agnes Stephens /|
|Tommy Duncan, CBO||Katie Duffell|
|E: email@example.com||E: firstname.lastname@example.org|
|T: +44 20 8481 9200||T: +44 20 7457 2020|